Dendreon Corp. (NASDAQ:DNDN): Brean Murray doesn’t buy Dendreon’s word that sales force departures, rather than competition, led to lower Provenge sales. The firm reported that physicians see the “clear utility of pre-chemo Zytiga,” which is affecting Provenge sales. Brean Murray maintains its Sell rating.
MDC Partners Inc. (NASDAQ:MDCA): Following MDC’s announcement of Q2 results that met RBC Capital requirements for being solid, the firm believes the company’s new business pipeline ought to fuel a growth in operating fundamentals, despite the timing of the new business being unsure. RBC forecasts that Q3 will be an inflection point for margin expansion and holds to an Outperform rating for the stock.
Accretive Health, Inc. (NYSE:AH): In JPMorgan’s eyes, Accretive Health’s settlement with the Minnesota State Attorney General takes away a big overhang and might lead to more settlements. The firm thinks shares will trade higher today and in weeks to come, and maintains an Overweight rating on the stocks. JPMorgan believes the settlement eases the risk of possible customer departures and promotes purchasing the stock.
Advent Software, Inc. (NASDAQ:ADVS): JMP Securities lowered its target on Advent Software due to wary comments issued by Advent. But JMP thinks the company turned in “generally solid” Q2 results, and views a number of positive catalysts coming for the company. Due to this, the firm still recommends buying shares.
Celadon Group Inc. (NYSE:CGI): Stifel Nicolaus raised its target on Celadon following the company’s announcement of higher than thought Q4 EPS. The firm still sees positive catalysts for the stock and reiterates a rating of Buy.
Don’t Miss: Gold and Silver Lessons from Pawn Stars.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.